
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

71894
10.1038/s41598-024-71894-2
Article
Association between the lipid accumulation product and chronic kidney disease among adults in the United States
Yu Xinxin 123
Pu Xing 123
Xi Yu 123
Li Xiang 123
http://orcid.org/0000-0002-9101-8032
Li Hailun lihailun101@sina.com

123
http://orcid.org/0000-0003-4604-7552
Zheng Donghui haeyzdh@163.com

123
1 https://ror.org/02sqxcg48 grid.470132.3 Department of Nephrology, The Affiliated Huai’an Hospital of Xuzhou Medical University and Huai’an Second People’s Hospital, Huai’an, China
2 grid.417303.2 0000 0000 9927 0537 Key Laboratory for Chronic Kidney Disease of Xuzhou Medical University, Xuzhou Medical University, Huai’an, China
3 grid.470132.3 Huai’an Key Laboratory of Chronic Kidney Disease, The Affiliated Huai’an Hospital of Xuzhou Medical University and Huai’an Second People’s Hospital, Huai’an, China
13 9 2024
13 9 2024
2024
14 2142312 6 2024
2 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The objective of this research was to explore the potential association between lipid accumulation product (LAP) and chronic kidney disease (CKD) among adult population of United States (US). Using cross-sectional data from the 2013 to 2018 National Health and Nutrition Examination Survey (NHANES), we explored the association of LAP with CKD, low estimated glomerular filtration rate (eGFR), and albuminuria. This analysis encompassed multivariate logistic regression analyses, smoothed curve fitting, subgroup analyses, and interaction tests. We found a significant positive association between higher ln-transformed LAP (LAP was transformed using a natural logarithm) and the prevalence of CKD, low-eGFR and albuminuria. Notably, this association of ln-transformed LAP with CKD and albuminuria was significantly influenced by diabetes status and sex (P for interaction < 0.05), while no significant interaction was observed regarding the association with low-eGFR (P for interaction > 0.05). Additionally, in model 3 (adjusted for all included covariates except eGFR and urinary albumin-creatinine ratio (UACR)), a nonlinear relationship was identified between ln-transformed LAP and the presence of both CKD and albuminuria, with inflection points of 4.57 and 4.49, respectively. This indicates that this correlation is more pronounced on the right of the inflection point. In conclusion, the findings indicate a significant association between LAP and the prevalence of CKD in US adults.

Keywords

National Health and Nutrition Examination Survey
Chronic kidney disease
Estimated glomerular filtration rate
Albuminuria
Lipid accumulation product
Obesity
Subject terms

Nephrology
Diseases
Kidney diseases
Huai'an City Science and Technology Program ProjectHAB202211 Scientific Research Project from Jiangsu Commission of Health of ChinaH2019062 Project of Science and Technology Development of Affiliated Hospital of Xuzhou Medical UniversityXYFM202248 National Natural Science Foundation of China82170757 issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Chronic kidney disease (CKD), a prevalent non-communicable disease, represents a significant contributor to the global mortality rate. Frequently designated as the “silent killer”, CKD is distinguished by its high prevalence, low awareness, and low cure rate1–3. It is estimated that more than 15% of the US population is affected by CKD, which equates to approximately 37 million individuals4. This condition significantly increases the probability of cardiovascular disease acquiring and augments the overall risk for mortality4. Therefore, it is of paramount importance to actively investigate novel biomarkers to facilitate the early recognition and intervention of CKD.

A growing body of evidence highlights the impact of obesity on the progression of CKD5–7. This relationship between obesity and CKD is mediated by a complex biological mechanism, including insulin resistance, lipotoxicity, and the dysregulation of adipokines5,7–9. It is, however, important to note that not all adipose tissue has a deleterious effect on renal health. In fact, visceral fat accumulation has the most profound adverse effects on renal function10. A cross-sectional study of the Korean population revealed a significantly higher prevalence of obesity among individuals with CKD compared to those without the condition. What’s more, the high occurrence of obesity was accompanied by an increase in visceral obesity11. The lipid accumulation product (LAP) initially proposed by Kahn, may be a more effective measure indicator of visceral fat accumulation compared to BMI, waist-to-hip ratio (WC), waist-to-hip ratio (WHR) and other indicators12,13. It is calculated by combining waist circumference (WC) and serum triglyceride (TG) levels, offering a convenience advantage over costly and complex imaging techniques such as magnetic resonance imaging (MRI) and/or computed tomography (CT)14. This approach is more suitable for large-scale health screening and disease risk assessment. The association between LAP and CKD has been evaluated in various regions and populations14–18. However, there are fewer reports on the relationship between LAP and CKD in the overall US population. Only the study by Bullen et al. showed an association between LAP and the occurrence of CKD, as well as a gradual deterioration in kidney function19. Hence, the primary objective of this study is to explore the connection between LAP and CKD among adult population of US.

Methods

Study design and participants

For this study, we used data from the public database of National Health and Nutrition Examination Survey (NHANES), which was conducted between 2013 and 2018 (https://www.cdc.gov/nchs/nhanes/index.html). NHANES assesses the health and nutritional status of the population of adults and children residing in the US using a mix of stratified, multistage, and probability sampling techniques20. All studies were subjected to a comprehensive review and received approval from the National Center for Health Statistics (NCHS) Research Ethics Review Board. Prior to participation, all participants provided written informed consent. Figure 1 illustrates the inclusion of 6,741 participants in the study after excluding those younger than 20 years, those with absences of data on CKD, estimated glomerular filtration rate (eGFR), urine albumin/creatinine ratio (UACR) and LAP, and pregnant individuals.Fig. 1 Flowchart of participants selection.

Variables

Within this investigation, LAP was regarded as an exposure variable and was determined by the subsequent formula: [WC (cm)—65] × [TG (mmol/L)] (males), and [WC (cm)—58] × [TG (mmol/L)] (females)21. Due to its skewed distribution, the LAP index was transformed using a natural logarithm (ln-transformed LAP).

CKD was regarded as outcome variable, along with low-eGFR and albuminuria, which are also analyzed as outcome variables. We used the CKD-EPI2021 equation recommended by the National Kidney Foundation to calculate eGFR22 (detailed information in supplementary material 1). CKD was characterized by UACR ≥ 30 mg/g or eGFR < 60 ml/min/1.73 m2 23. The criterion for low-eGFR was specifically designated as eGFR < 60 ml/min/1.73 m2, while albuminuria was designated as UACR ≥ 30 mg/g.

In our study, we incorporated a range of demographic and clinical variables as covariates to ensure the robustness of our analysis. These included age, sex, race, poverty-to-income ratio (PIR), education level, and lifestyle factors such as drinking and smoking status. Anthropometric and biochemical measures were also considered, encompassing BMI, weight, high-density lipoprotein cholesterol (HDL-cholesterol), low-density lipoprotein cholesterol (LDL-cholesterol), blood urea nitrogen (BUN), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT). Furthermore, the potential influence of hypertension and diabetes was considered. The NHANES website provides a comprehensive information about the interpretation, and measurement, along with the calculation of every variable. The definitions of the variables involved are given in supplementary material 2.

Statistical analysis

Continuous variables were expressed as mean ± standard deviation and categorical variables were represented as percentages. The demographic characteristics of the participants were evaluated based on the classification of CKD using weighted chi-square (categorical variables) and weighted linear regression model (continuous variables). To examine the association of ln-transformed LAP with CKD, low-eGFR, and albuminuria, multifactorial linear regression analysis was conducted, controlling for potential confounding variables. Model 1 was not adjusted for covariates. Model 2 was adjusted for age, sex, and race. Model 3 incorporated additional variables, including education, PIR, weight, BMI, HDL-cholesterol, LDL-cholesterol, ALP, ALT, AST, BUN, albumin, alcohol use, cigarette use, as well as hypertension and diabetes status. Furthermore, generalized additive models and smoothed curve fitting were employed to examine the nonlinear association between ln-transformed LAP with outcome variables. To further explore the relationship between them, stratified analyses were performed according to sex, age, BMI, as well as hypertension and diabetes status. All statistical analyses were performed using R (version 4.2.3) and Empowerstats (version 2.0). We considered statistical significance as P < 0.05.

Results

Baseline characteristics

A total of 6,741 participants were enrolled in the study, with a mean age of 48.33 ± 16.82 years. The population consisted of 49.53% males and 50.47% females. A total of 1,142 individuals were diagnosed with CKD (weighted percentage 13.24). As detailed in in Table 1, individuals with CKD were more likely to be of advanced age, female sex, and non-Hispanic Black ethnicity. Additionally, they exhibited a higher prevalence of diabetes and higher levels of BMI, BUN, ALP, AST, UACR, and ln-transformed LAP. In contrast, these individuals exhibited lower levels of education, PIR, LDL-C, albumin, eGFR. Furthermore, they were less likely to engage in smoking and alcohol consumption. Table 1 Baseline characteristics of study participants grouped by CKD status.

Characteristic	Overall (N = 6741)	Non-CKD (N = 5599)	CKD (N = 1142)	P value	
Age (year)	48.33 ± 16.82	46.52 ± 16.01	60.20 ± 17.13	 < 0.0001	
Sex (%)				 < 0.0001	
Male	49.53	50.64	42.25		
Female	50.47	49.36	57.75		
Race (%)				0.0025	
Mexican American	8.81	8.85	8.57		
Other Hispanic	6.29	6.46	5.16		
Non-Hispanic white	65.20	65.33	64.34		
Non-Hispanic black	10.51	9.97	14.05		
Other races	9.19	9.39	7.88		
Education level (%)				 < 0.0001	
Under high school	14.02	13.20	19.43		
High school or equivalent	23.33	22.55	28.44		
Above high school	62.62	64.23	52.06		
Unknown	0.02	0.01	0.08		
PIR (%)	2.93 ± 1.60	2.98 ± 1.60	2.62 ± 1.54	0.0001	
Weight (kg)	83.58 ± 22.13	83.51 ± 21.83	84.04 ± 24.03	0.5054	
BMI (kg/m2)	29.36 ± 7.07	29.18 ± 6.97	30.51 ± 7.60	 < 0.0001	
HDL-cholesterol (mmol/L)	1.42 ± 0.44	1.41 ± 0.42	1.43 ± 0.56	0.4206	
LDL-cholesterol (mmol/L)	2.90 ± 0.91	2.91 ± 0.89	2.81 ± 1.00	0.0019	
BUN (mmol/L)	5.06 ± 1.85	4.86 ± 1.48	6.37 ± 3.09	 < 0.0001	
Albumin (g/L)	42.13 ± 3.39	42.30 ± 3.32	40.99 ± 3.66	 < 0.0001	
ALP (IU/L)	69.22 ± 23.91	68.12 ± 22.25	76.44 ± 31.87	 < 0.0001	
AST (U/L)	24.24 ± 17.11	24.02 ± 16.33	25.66 ± 21.48	0.0077	
ALT (U/L)	24.51 ± 16.56	24.59 ± 16.26	23.95 ± 18.43	0.2814	
eGFR (mL/min/1.73 m2)	96.42 ± 20.36	99.12 ± 17.17	78.70 ± 28.95	 < 0.0001	
UACR (mg/g)	33.45 ± 242.56	7.91 ± 5.29	200.85 ± 641.79	 < 0.0001	
Ln-transformed LAP (cm × mmol/L)	3.63 ± 0.89	3.59 ± 0.88	3.89 ± 0.88	 < 0.0001	
Alcohol use (%)				0.0005	
Yes	78.36	78.94	74.62		
No	16.75	16.07	21.23		
Unknown	4.88	5.00	4.15		
Cigarette use (%)				 < 0.0001	
Every day	14.73	14.78	14.42		
Some days	3.74	3.99	2.08		
Not at all	26.24	25.12	33.61		
Unknown	55.29	56.11	49.88		
Hypertension (%)				0.0908	
No	5.32	5.50	4.14		
Yes	94.68	94.50	95.86		
Diabetes (%)				 < 0.0001	
No	84.61	88.07	61.89		
Yes	15.39	11.93	38.11		
Low-eGFR (%)				 < 0.0001	
No	94.97	100	62.01		
Yes	5.03	0	37.99		
Albuminuria (%)				 < 0.0001	
No	90.19	100	25.91		
Yes	9.81	0	74.09		
Mean ± SD for continuous variables: P value was calculated by weighted linear regression model. (%) for categorical variables: P value was calculated by weighted chi-square test.

CKD, chronic kidney disease; PIR, poverty-to-income ratio; BMI, body mass index; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; BUN, blood urea nitrogen; ALP, alkaline phosphatase; ALT: alanine transaminase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; UACR, urine albumin-to-creatinine ratio; LAP, lipid accumulation product.

Association of ln-transformed LAP with CKD, low-eGFR and albuminuria

Results showed a significant and positive association of ln-transformed LAP with CKD (Table 2). The positive association still existed after accounting for potential confounders. Specifically, there was a 52% higher odds of CKD prevalence when the ln-transformed LAP increased by one unit in Model 1 (OR:1.52, 95% CI 1.40, 1.64). Similarly, the odds increased by 35% in Model 3 (OR:1.35, 95% CI 1.18,1.55). Notably, when ln-transformed LAP was categorized into quartiles, individuals in the highest quartile exhibited a 57% increased odds of CKD prevalence compared to those in the lowest quartile in Model 3 (OR:1.57, 95% CI 1.15, 2.15; P for trend = 0.005). Table 2 Association between the ln-transformed LAP and CKD, low-eGFR and albuminuria.

Exposure	Model 1 OR (95% CI), p value	Model 2 OR (95% CI), p value	Model 3 OR (95% CI), p value	
CKD	
 Ln-transformed LAP (continuous)	1.52 (1.40, 1.64) < 0.0001	1.44 (1.32, 1.58) < 0.0001	1.35 (1.18, 1.55) < 0.0001	
 Ln-transformed LAP (categories)	
 Q1	Reference	Reference	Reference	
 Q2	1.59 (1.30, 1.94) < 0.0001	1.14 (0.92, 1.41) 0.2477	1.17 (0.91, 1.49) 0.2159	
 Q3	1.81 (1.49, 2.21) < 0.0001	1.26 (1.02, 1.56) 0.0337	1.18 (0.90, 1.55) 0.2246	
 Q4	2.49 (2.06, 3.02) < 0.0001	1.96 (1.59, 2.41) < 0.0001	1.57 (1.15, 2.15) 0.0043	
 P for trend	 < 0.0001	 < 0.0001	0.0050	
Low-eGFR	
 Ln-transformed LAP (continuous)	1.40 (1.25, 1.57) < 0.0001	1.48 (1.27, 1.71) < 0.0001	1.48 (1.14, 1.91) 0.0027	
 Ln-transformed LAP (categories)	
 Q1	Reference	Reference	Reference	
 Q2	2.05 (1.50, 2.79) < 0.0001	1.36 (0.96, 1.92) 0.0797	1.43 (0.93, 2.21) 0.1061	
 Q3	2.24 (1.65, 3.04) < 0.0001	1.59 (1.13, 2.24) 0.0075	1.77 (1.10, 2.86) 0.0195	
 Q4	2.37 (1.75, 3.20) < 0.0001	2.07 (1.46, 2.91) < 0.0001	1.93 (1.10, 3.38) 0.0218	
 P for trend	 < 0.0001	 < 0.0001	0.0196	
Albuminuria	
 Ln-transformed LAP (continuous)	1.52 (1.40, 1.66) < 0.0001	1.47 (1.34, 1.62) < 0.0001	1.34 (1.16, 1.55) < 0.0001	
 Ln-transformed LAP (categories)	
 Q1	Reference	Reference	Reference	
 Q2	1.41 (1.12, 1.77) 0.0033	1.11 (0.88, 1.41) 0.3769	1.11 (0.86, 1.45) 0.4210	
 Q3	1.62 (1.30, 2.03) < 0.0001	1.23 (0.98, 1.55) 0.0786	1.09 (0.82, 1.46) 0.5549	
 Q4	2.46 (1.99, 3.04) < 0.0001	2.04 (1.63, 2.55) < 0.0001	1.54 (1.10, 2.13) 0.0108	
 P for trend	 < 0.0001	 < 0.0001	0.0108	
Data are presented as odds ratios, 95% confidence intervals, and P-value.

Model 1: no covariates were adjusted.

Model 2: age, sex, and race were adjusted.

Model 3: age, sex, race, education, PIR, weight, BMI, HDL-cholesterol, LDL-cholesterol, ALP, ALT, AST, BUN, albumin, alcohol use, cigarette use, hypertension and diabetes were adjusted.

Similarly, a positive connection was noted between the ln-transformed LAP and both low-eGFR and albuminuria. An analysis of Model 3 data indicated that for each one-unit increase in ln-transformed LAP, there was a 48% higher odds ratio for the prevalence of low-eGFR (OR:1.48, 95% CI 1.14, 1.91) and a 34% higher odds ratio for the prevalence of albuminuria (OR: 1.34, 95% CI 1.16, 1.55). Upon categorizing ln-transformed LAP into quartiles, individuals in the highest quartile of model 3 exhibited 93% increased odds of having low-eGFR compared to those in the lowest quartile, as well as 54% increased odds of having albuminuria (low-eGFR, OR:1.93, 95% CI 1.10, 3.38; P for trend = 0.0196; albuminuria, OR: 1.54, 95% CI 1.10, 2.13; p for trend = 0.0108).

The application of generalized additive models and smoothed curve fitting provided further evidence of correlation between ln-transformed LAP and three outcome variables in Model 3. As illustrated in Fig. 2, a U-shaped nonlinear relationship was identified between ln-transformed LAP and CKD and albuminuria, with inflection points of 4.57 and 4.49, respectively (Table 3). This indicates that this correlation is more pronounced on the right of the inflection point.Fig. 2 The association between ln-transformed LAP and CKD/low-eGFR/albuminuria. Red line represents the smooth curve fit between variables. Blue lines represent the 95% of confidence interval from the fit.

Table 3 Threshold effect analysis of ln-transformed LAP on CKD, low-eGFR and albuminuria using two-piecewise linear regression model.

Exposure	OR (95% CI), p value	
CKD	
 Fitting by the standard linear model	1.35 (1.18, 1.55) < 0.0001	
 Fitting by the two-piecewise linear model		
 Inflection point (cm × mmol/L)	4.57	
 Ln-transformed LAP < 4.57	1.18 (1.01, 1.38) 0.0417	
 Ln-transformed LAP > 4.57	2.34 (1.65, 3.32) < 0.0001	
 Log likelihood ratio test	 < 0.001	
Low-eGFR	
 Fitting by the standard linear model	1.48 (1.14, 1.91) 0.0027	
 Fitting by the two-piecewise linear model		
 Inflection point (cm × mmol/L)	4.13	
 Ln-transformed LAP < 4.13	1.73 (1.23, 2.43) 0.0016	
 Ln-transformed LAP > 4.13	1.11 (0.69, 1.79) 0.6634	
 Log likelihood ratio test	0.155	
Albuminuria	
 Fitting by the standard linear model	1.34 (1.16, 1.55) < 0.0001	
 Fitting by the two-piecewise linear model		
 Inflection point (cm × mmol/L)	4.49	
 Ln-transformed LAP < 4.49	1.14 (0.97, 1.35) 0.1193	
 Ln-transformed LAP > 4.49	2.24 (1.62, 3.10) < 0.0001	
 Log likelihood ratio test	 < 0.001	
The model adjusted for age, sex, race, education, PIR, weight, BMI, HDL-cholesterol, LDL-cholesterol, ALP, ALT, AST, BUN, albumin, alcohol use, cigarette use, hypertension and diabetes.

Subgroup analysis

To ascertain whether the findings were consistent across different subgroups as they were in the total population, we performed subgroup analyses. Table 4 presents the results, which demonstrate a positive association between ln-transformed LAP and both CKD and albuminuria in subgroups stratified by sex, age, BMI, as well as diabetes and hypertension status. However, this association was not statistically significant in female participants and those with a BMI ≤ 25 kg/m2 (P > 0.05). It is noteworthy that in participants aged 20 to less than 40 years, there was a negative but not statistically significant association between the ln-transformed LAP and low-eGFR (OR: 0.87, 95% CI 0.37, 2.05, P > 0.05). While other subgroups exhibited a positive association, this was not statistically significant in female participants and those with a BMI between 25 and 30 kg/m2. Further interaction tests revealed that sex, age, BMI, and diabetes and hypertension status did not have statistically significant impact on the association between ln-transformed LAP with low-eGFR (P for interaction > 0.05), suggesting that these factors did not have a significant effect on this positive association. In contrast, sex and diabetes status may influence the association between ln-transformed LAP and CKD and albuminuria (P for interaction < 0.05), with the association being more pronounced in male and patients with diabetic. Table 4 Association between ln-transformed LAP on CKD, low-eGFR and albuminuria in different subgroups.

Subgroups	CKD	Low-eGFR	Albuminuria	
OR (95% CI)	P for interaction	OR (95% CI)	P for interaction	OR (95% CI)	P for interaction	
Sex		0.0080		0.3010		0.0091	
Male	1.50 (1.28, 1.76)		1.58 (1.19, 2.11)		1.49 (1.26, 1.76)		
Female	1.17 (0.98, 1.39)		1.32 (0.95, 1.84)		1.15 (0.96, 1.39)		
Age (year)		0.0349		0.1302		0.1974	
20 ≤ Age < 40	1.54 (1.26, 1.89)		0.87 (0.37, 2.05)		1.42 (1.15, 1.74)		
40 ≤ Age < 60	1.69 (1.40, 2.05)		2.17 (1.41, 3.35)		1.56 (1.28, 1.90)		
60 ≤ Age	1.29 (1.09, 1.53)		1.61 (1.23, 2.11)		1.27 (1.05, 1.53)		
BMI (kg/m2)		0.0530		0.3963		0.0234	
BMI ≤ 25	1.22 (0.98, 1.52)		1.83 (1.18, 2.83)		1.18 (0.95, 1.48)		
25 < BMI < 30	1.26 (1.02, 1.57)		1.41 (0.96, 2.06)		1.27 (1.00, 1.60)		
30 ≤ BMI	1.64 (1.35, 2.00)		1.27 (0.89, 1.83)		1.70 (1.39, 2.09)		
Hypertension		0.0345		0.0535		0.1867	
No	2.27 (1.35, 3.83)		4.56 (1.25, 16.68)		1.87 (1.10, 3.19)		
Yes	1.33 (1.16, 1.53)		1.44 (1.12, 1.86)		1.33 (1.15, 1.54)		
Diabetes		0.0009		0.8243		0.0029	
No	1.21 (1.04, 1.41)		1.50 (1.13, 1.99)		1.20 (1.02, 1.41)		
Yes	1.71 (1.41, 2.08)		1.44 (1.01, 2.04)		1.64 (1.35, 2.00)		
Age, sex, race, education, PIR, weight, BMI, HDL-cholesterol, LDL-cholesterol, ALP, ALT, AST, BUN, albumin, alcohol use, cigarette use, hypertension and diabetes were adjusted were adjusted. In the subgroup analyses, the model is not adjusted for the stratification variable itself.

Discussion

The present study, which included 6741 participants, has research revealed a significant positive correlation between higher levels of ln-transformed LAP and CKD, low-eGFR, and albuminuria among adult population of US. Moreover, the study indicates that the association of ln-transformed LAP with CKD and albuminuria was significantly influenced by sex and diabetes status. It is also noteworthy that the data exhibit a U-shaped nonlinear relationship, with inflection points at 4.57 and 4.49, respectively. This implies that beyond the inflection points, continued elevation of ln-transformed LAP levels would significantly increase the risk of CKD. Understanding these inflection points can help in risk assessment and stratification of individuals.

Various investigations have demonstrated that LAP could function as a promising indicator for a range of health disorders, including metabolic syndrome24,25, osteoarthritis21, diabetic nephropathy26, and metabolic dysfunction-associated fatty liver disease (MAFLD)27. The findings of our results corroborate this notion, revealing a positive correlation between higher ln-transformed LAP and odds of CKD prevalence. In accordance with previous research results, in cross-sectional studies of Korean adults15, a rural population in Northeast China16, and a population in East China17, respectively, it was found that LAP was a good predictor of low-eGFR. In female subjects, LAP was better recognized than conventional indicators (BMI, WC)16. In addition, a cross-sectional investigation by Yan et al. on a Chinese population aged 40 years and older has demonstrated a strong association of elevated LAP with higher odds of CKD in adult females, a correlation that was not observed in males14. Notably, Tang et al. have found a positive correlation between LAP and diabetic kidney disease (DKD) in patients with 2 diabetics26. Another cohort study of non-diabetic Iranian adults found that LAP could not serve as a reliable predictor of decreased eGFR18. Nevertheless, our findings indicate that diabetes status did not alter the association between ln-transformed LAP and low-eGFR. However, sex and diabetes status exerted a significant influence on the association of ln-transformed LAP with CKD. This association was particularly pronounced in males and diabetic patients. It has been demonstrated that the accumulation and distribution of body fat are influenced by sex hormone levels, with males typically exhibiting a higher amount of visceral fat. Additionally, postmenopausal females may have a significant rise in visceral fat due to the decline in estrogen levels28. These hormonal variations may contribute to some of the observed discrepancies in study findings, along with factors such as age, race, covariates adjustment, and study design. Further studies are necessary to gain a more comprehensive understanding of the association between LAP and CKD.

The etiology of the link between obesity and CKD is intricate and multifaceted. On the one hand, it can be understood as a crosstalk between the “adipose-renal axis”, which is primarily characterized by the secretion of adipokines, cytokines, and metabolites from adipose tissue that subsequently affect kidney health29. It is widely recognized that persistent, low-grade chronic inflammation plays a pivotal role in the adverse outcomes observed in individuals with CKD30. Meanwhile, obesity is frequently linked to chronic inflammation of adipose tissue31. Consequently, therapeutic interventions that target inflammation have attracted considerable interest in the context of CKD. It has been demonstrated that in the context of obesity, a notable increased number of macrophages within adipose tissue, accompanied by a polarization shift towards a pro-inflammatory state (M1). This shift enhances the generation of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-12 (IL-12)32, while concurrently reducing the secretion of anti-inflammatory adipokines, such as lipofuscin33. This series of events ultimately leads to renal injury. In contrast, relevant investigations have demonstrated that the generation of uremic toxins in individuals afflicted with CKD contributes to insulin resistance and inflammation in adipose tissue31,34. More importantly, the occurrence of localized inflammation within adipocytes is correlated with reduced insulin sensitivity35. Adipocytes are a significant contributor to the presence of inflammatory cytokines in circulatory systems. Consequently, interventions aimed at adipose tissue inflammation may offer a promising approach to ameliorating renal impairment associated with excessive adiposity. On the other hand, the lipid nephrotoxicity hypothesis also warrants consideration as an important factor. A high-fat diet has been demonstrated to promote lipid accumulation in mice, a process that is thought to occur via the vascular endothelial growth factor-B (VEGF-B) signaling pathway, mitochondrial damage and the subsequent enhancement of insulin resistance, the generation of reactive oxygen species, and endoplasmic reticulum stress, all of which eventually resulted in renal impairment36–38. Furthermore, obesity is a recognized risk factor fo the onset of various chronic diseases, including hepatic steatosis, atherosclerosis, hypertension, hyperlipidemia, and others, which also result in the deterioration of renal function.

It is imperative to acknowledge the multitude of strengths in this research. First, the study’s population is nationally representative, thereby enhancing the generalizability of the findings. Secondly, the analysis was adjusted for relevant confounders variables, thus ensuring the reliability of the results. In addition, subgroup analysis was performed. Most importantly, LAP, with its straightforward calculation, emerges as a potentially tool for identifying individuals at increased odds of CKD prevalence. It is nevertheless imperative to recognize the constraints of our study. The cross-sectional nature of our research design precludes the determination of a causal relationship between the exposed and outcome variables. Furthermore, confounding factors that were not accounted for in the analysis may also have an impact. Although previous studies have indicated that the correlation between obesity and CKD is not evident in patients with CKD stage 4/511, our study did not further categorize CKD by stage to investigate this association.

Conclusion

The present study demonstrated a notable positive association of higher ln-transformed LAP with CKD. This finding underscores the potential utility of LAP as a biomarker for identifying individuals odds of CKD prevalence. However, additional comprehensive prospective studies are imperative to substantiate this discovery.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71894-2.

Acknowledgements

We express our gratitude to the personnel and individuals involved in the NHANES project for their invaluable contributions.

Author contributions

X.Y., X.P., Y.X. and X.L. designed the research. X.Y., X.P. and Y.X. collected, analyzed the data, and drafed the manuscript. X.Y., X.P., H.L. and D.Z. revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

The funding was supported by the National Natural Science Foundation of China (82170757), Huai’an City Science and Technology Program Project (HAB202211), Scientific Research Project from Jiangsu Commission of Health of China (H2019062), Project of Science and Technology Development of Affiliated Hospital of Xuzhou Medical University (XYFM202248).

Data availability

All anonymized data were obtained from the NHANES open database (https://www.cdc.gov/nchs/nhanes/index). For further consultations, contact the corresponding author.

Competing interests

The authors declare no competing interests.

Ethics statement

The survey protocol for the NHANES was approved by CDC’s National Center for Health Statistics Institutional Research Ethics Review Board. The protocol descriptions are available at (https://www.cdc.gov/nchs/nhanes/irba98.htm). The methods involved in this study are carried out in accordance with relevant guidelines and regulations (Helsinki Declaration). Prior to their participation in the study, all subjects and/or their legal guardian(s) were written informed consent.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Xinxin Yu and Xing Pu.
==== Refs
References

1. Shlipak MG The case for early identification and intervention of chronic kidney disease: Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference Kidney Int. 2021 99 34 47 10.1016/j.kint.2020.10.012 33127436
Shlipak, M. G. et al. The case for early identification and intervention of chronic kidney disease: Conclusions from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int. 99, 34–47 (2021).33127436 10.1016/j.kint.2020.10.012
2. McMahon GM Hwang S-J Fox CS Residual lifetime risk of chronic kidney disease Nephrol. Dial. Transpl. 2016 32 gfw253 10.1093/ndt/gfw253
McMahon, G. M., Hwang, S.-J. & Fox, C. S. Residual lifetime risk of chronic kidney disease. Nephrol. Dial. Transpl. 32, gfw253 (2016).10.1093/ndt/gfw253
3. Kovesdy CP Epidemiology of chronic kidney disease: An update 2022 Kidney Int. Suppl. 2022 12 7 11 10.1016/j.kisu.2021.11.003
Kovesdy, C. P. Epidemiology of chronic kidney disease: An update 2022. Kidney Int. Suppl. 12, 7–11 (2022).10.1016/j.kisu.2021.11.003
4. Vassalotti JA Boucree SC Integrating CKD Into US primary care: Bridging the knowledge and implementation gaps Kidney Int. Rep. 2022 7 389 396 10.1016/j.ekir.2022.01.1066 35257053
Vassalotti, J. A. & Boucree, S. C. Integrating CKD Into US primary care: Bridging the knowledge and implementation gaps. Kidney Int. Rep. 7, 389–396 (2022).35257053 10.1016/j.ekir.2022.01.1066
5. Nawaz S Obesity and chronic kidney disease: A current review Obes. Sci. Pract. 2023 9 61 74 10.1002/osp4.629 37034567
Nawaz, S. et al. Obesity and chronic kidney disease: A current review. Obes. Sci. Pract. 9, 61–74 (2023).37034567 10.1002/osp4.629
6. Ejerblad E Obesity and risk for chronic renal failure J. Am. Soc. Nephrol. 2006 17 1695 1702 10.1681/ASN.2005060638 16641153
Ejerblad, E. et al. Obesity and risk for chronic renal failure. J. Am. Soc. Nephrol. 17, 1695–1702 (2006).16641153 10.1681/ASN.2005060638
7. Jiang Z Obesity and chronic kidney disease Am. J. Physiol-endoc. M. 2023 324 E24 E41
Jiang, Z. et al. Obesity and chronic kidney disease. Am. J. Physiol-endoc. M. 324, E24–E41 (2023).
8. Seng NSHL Lohana P Chandra S Jim B The fatty kidney and beyond: A silent epidemic Am. J. Med. 2023 136 965 974 10.1016/j.amjmed.2023.06.025 37451390
Seng, N. S. H. L., Lohana, P., Chandra, S. & Jim, B. The fatty kidney and beyond: A silent epidemic. Am. J. Med. 136, 965–974 (2023).37451390 10.1016/j.amjmed.2023.06.025
9. Gai Z Lipid accumulation and chronic kidney disease Nutrients 2019 11 722 10.3390/nu11040722 30925738
Gai, Z. et al. Lipid accumulation and chronic kidney disease. Nutrients 11, 722 (2019).30925738 10.3390/nu11040722
10. Stefan N Obesity and renal disease: Not all fat is created equal and not all obesity is harmful to the kidneys Nephrol. Dial. Transpl. 2016 31 726 730 10.1093/ndt/gfu081
Stefan, N. et al. Obesity and renal disease: Not all fat is created equal and not all obesity is harmful to the kidneys. Nephrol. Dial. Transpl. 31, 726–730 (2016).10.1093/ndt/gfu081
11. Evangelista LS Cho W-K Kim Y Obesity and chronic kidney disease: A population-based study among South Koreans PLoS One 2018 13 e0193559 10.1371/journal.pone.0193559 29489920
Evangelista, L. S., Cho, W.-K. & Kim, Y. Obesity and chronic kidney disease: A population-based study among South Koreans. PLoS One 13, e0193559 (2018).29489920 10.1371/journal.pone.0193559
12. Kahn HS The ‘lipid accumulation product’ performs better than the body mass index for recognizing cardiovascular risk: A population-based comparison BMC Cardiovasc. Disord. 2005 5 26 10.1186/1471-2261-5-26 16150143
Kahn, H. S. The ‘lipid accumulation product’ performs better than the body mass index for recognizing cardiovascular risk: A population-based comparison. BMC Cardiovasc. Disord. 5, 26 (2005).16150143 10.1186/1471-2261-5-26
13. Chen T Zhao C Relationship between visceral adipose index, lipid accumulation product and type 2 diabetes mellitus Adv. Clin. Med. 2022 12 3350 10.12677/ACM.2022.124484
Chen, T. & Zhao, C. Relationship between visceral adipose index, lipid accumulation product and type 2 diabetes mellitus. Adv. Clin. Med. 12, 3350 (2022).10.12677/ACM.2022.124484
14. Yan P Association of lipid accumulation product with chronic kidney disease in Chinese community adults: A report from the REACTION study Lipids Health Dis. 2021 20 131 10.1186/s12944-021-01569-8 34627270
Yan, P. et al. Association of lipid accumulation product with chronic kidney disease in Chinese community adults: A report from the REACTION study. Lipids Health Dis. 20, 131 (2021).34627270 10.1186/s12944-021-01569-8
15. Seong JM Gender difference in the association of chronic kidney disease with visceral adiposity index and lipid accumulation product index in Korean adults: Korean National Health and Nutrition Examination Survey Int. Urol. Nephrol. 2021 53 1417 1425 10.1007/s11255-020-02735-0 33389514
Seong, J. M. et al. Gender difference in the association of chronic kidney disease with visceral adiposity index and lipid accumulation product index in Korean adults: Korean National Health and Nutrition Examination Survey. Int. Urol. Nephrol. 53, 1417–1425 (2021).33389514 10.1007/s11255-020-02735-0
16. Dai D Visceral adiposity index and lipid accumulation product index: Two alternate body indices to identify chronic kidney disease among the rural population in Northeast China Int. J. Environ. Res. Public. Health 2016 13 1231 10.3390/ijerph13121231 27983609
Dai, D. et al. Visceral adiposity index and lipid accumulation product index: Two alternate body indices to identify chronic kidney disease among the rural population in Northeast China. Int. J. Environ. Res. Public. Health 13, 1231 (2016).27983609 10.3390/ijerph13121231
17. Zhang K Li Q Chen Y Wang N Lu Y Visceral adiposity and renal function: An observational study from SPECT-China Lipids Health Dis. 2017 16 205 10.1186/s12944-017-0597-0 29078775
Zhang, K., Li, Q., Chen, Y., Wang, N. & Lu, Y. Visceral adiposity and renal function: An observational study from SPECT-China. Lipids Health Dis. 16, 205 (2017).29078775 10.1186/s12944-017-0597-0
18. Mousapour P Predictive performance of lipid accumulation product and visceral adiposity index for renal function decline in non-diabetic adults, an 8.6-year follow-up Clin. Exp. Nephrol. 2020 24 225 234 10.1007/s10157-019-01813-7 31734819
Mousapour, P. et al. Predictive performance of lipid accumulation product and visceral adiposity index for renal function decline in non-diabetic adults, an 8.6-year follow-up. Clin. Exp. Nephrol. 24, 225–234 (2020).31734819 10.1007/s10157-019-01813-7
19. Bullen AL Lipid accumulation product, visceral adiposity index and risk of chronic kidney disease Bmc Nephrol. 2022 23 401 10.1186/s12882-022-03026-9 36522626
Bullen, A. L. et al. Lipid accumulation product, visceral adiposity index and risk of chronic kidney disease. Bmc Nephrol. 23, 401 (2022).36522626 10.1186/s12882-022-03026-9
20. Chen W Association between dietary zinc intake and abdominal aortic calcification in US adults Nephrol. Dial. Transplant. 2020 35 1171 1178 10.1093/ndt/gfz134 31298287
Chen, W. et al. Association between dietary zinc intake and abdominal aortic calcification in US adults. Nephrol. Dial. Transplant. 35, 1171–1178 (2020).31298287 10.1093/ndt/gfz134
21. Huang J Association between lipid accumulation products and osteoarthritis among adults in the United States: A cross-sectional study, NHANES 2017–2020 Prev. Med. 2024 180 107861 10.1016/j.ypmed.2024.107861 38244933
Huang, J. et al. Association between lipid accumulation products and osteoarthritis among adults in the United States: A cross-sectional study, NHANES 2017–2020. Prev. Med. 180, 107861 (2024).38244933 10.1016/j.ypmed.2024.107861
22. Miller WG National kidney foundation laboratory engagement working group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: practical guidance for clinical laboratories Clin. Chem. 2022 68 511 520 10.1093/clinchem/hvab278 34918062
Miller, W. G. et al. National kidney foundation laboratory engagement working group recommendations for implementing the CKD-EPI 2021 race-free equations for estimated glomerular filtration rate: practical guidance for clinical laboratories. Clin. Chem. 68, 511–520 (2022).34918062 10.1093/clinchem/hvab278
23. Chapter 1: Definition and classification of CKD. Kidney Int. Suppl (2011) 3, 19–62 (2013).
24. Chen Z-Y Lipid accumulation product is a better predictor of metabolic syndrome in Chinese adolescents: A cross-sectional study Front. Endocrinol. (Lausanne) 2023 14 1179990 10.3389/fendo.2023.1179990 37424867
Chen, Z.-Y. et al. Lipid accumulation product is a better predictor of metabolic syndrome in Chinese adolescents: A cross-sectional study. Front. Endocrinol. (Lausanne) 14, 1179990 (2023).37424867 10.3389/fendo.2023.1179990
25. Li Y Association between four anthropometric indexes and metabolic syndrome in US Adults Front. Endocrinol. 2022 13 889785 10.3389/fendo.2022.889785
Li, Y. et al. Association between four anthropometric indexes and metabolic syndrome in US Adults. Front. Endocrinol. 13, 889785 (2022).10.3389/fendo.2022.889785
26. Tang M Interrelation between the lipid accumulation product index and diabetic kidney disease in patients with type 2 diabetes mellitus Front. Endocrinol. 2023 14 1224889 10.3389/fendo.2023.1224889
Tang, M. et al. Interrelation between the lipid accumulation product index and diabetic kidney disease in patients with type 2 diabetes mellitus. Front. Endocrinol. 14, 1224889 (2023).10.3389/fendo.2023.1224889
27. Li H Zhang Y Luo H Lin R The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults Front. Endocrinol. (Lausanne) 2022 13 977625 10.3389/fendo.2022.977625 36407325
Li, H., Zhang, Y., Luo, H. & Lin, R. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults. Front. Endocrinol. (Lausanne) 13, 977625 (2022).36407325 10.3389/fendo.2022.977625
28. Kataoka H Nitta K Hoshino J Visceral fat and attribute-based medicine in chronic kidney disease Front. Endocrinol. 2023 14 1097596 10.3389/fendo.2023.1097596
Kataoka, H., Nitta, K. & Hoshino, J. Visceral fat and attribute-based medicine in chronic kidney disease. Front. Endocrinol. 14, 1097596 (2023).10.3389/fendo.2023.1097596
29. Brennan E Kantharidis P Cooper ME Godson C Pro-resolving lipid mediators: Regulators of inflammation, metabolism and kidney function Nat. Rev. Nephrol. 2021 17 725 739 10.1038/s41581-021-00454-y 34282342
Brennan, E., Kantharidis, P., Cooper, M. E. & Godson, C. Pro-resolving lipid mediators: Regulators of inflammation, metabolism and kidney function. Nat. Rev. Nephrol. 17, 725–739 (2021).34282342 10.1038/s41581-021-00454-y
30. Ebert T Inflammation and premature ageing in chronic kidney disease Toxins 2020 12 227 10.3390/toxins12040227 32260373
Ebert, T. et al. Inflammation and premature ageing in chronic kidney disease. Toxins 12, 227 (2020).32260373 10.3390/toxins12040227
31. Arabi T Obesity-related kidney disease: Beyond hypertension and insulin-resistance Front. Endocrinol. 2023 13 1095211 10.3389/fendo.2022.1095211
Arabi, T. et al. Obesity-related kidney disease: Beyond hypertension and insulin-resistance. Front. Endocrinol. 13, 1095211 (2023).10.3389/fendo.2022.1095211
32. Lumeng CN Bodzin JL Saltiel AR Obesity induces a phenotypic switch in adipose tissue macrophage polarization J. Clin. Invest. 2007 117 175 184 10.1172/JCI29881 17200717
Lumeng, C. N., Bodzin, J. L. & Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117, 175–184 (2007).17200717 10.1172/JCI29881
33. Zhu Q Scherer PE Immunologic and endocrine functions of adipose tissue: Implications for kidney disease Nat. Rev. Nephrol. 2018 14 105 120 10.1038/nrneph.2017.157 29199276
Zhu, Q. & Scherer, P. E. Immunologic and endocrine functions of adipose tissue: Implications for kidney disease. Nat. Rev. Nephrol. 14, 105–120 (2018).29199276 10.1038/nrneph.2017.157
34. D’Apolito M Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure J. Clin. Invest. 2010 120 203 213 10.1172/JCI37672 19955654
D’Apolito, M. et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J. Clin. Invest. 120, 203–213 (2010).19955654 10.1172/JCI37672
35. Bensussen A Torres-Magallanes JA Roces De Álvarez-Buylla E Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue Front. Immunol. 2023 14 1014778 10.3389/fimmu.2023.1014778 37026009
Bensussen, A., Torres-Magallanes, J. A. & Roces De Álvarez-Buylla, E. Molecular tracking of insulin resistance and inflammation development on visceral adipose tissue. Front. Immunol. 14, 1014778 (2023).37026009 10.3389/fimmu.2023.1014778
36. Lieben L Lipid toxicity drives renal disease Nat. Rev. Nephrol 2017 13 194 194 10.1038/nrneph.2017.22 28239170
Lieben, L. Lipid toxicity drives renal disease. Nat. Rev. Nephrol 13, 194–194 (2017).28239170 10.1038/nrneph.2017.22
37. Aguilar A Shielding mitochondria from lipotoxicity prevents renal injury Nat. Rev. Nephrol. 2016 12 580 580 10.1038/nrneph.2016.132 27573730
Aguilar, A. Shielding mitochondria from lipotoxicity prevents renal injury. Nat. Rev. Nephrol. 12, 580–580 (2016).27573730 10.1038/nrneph.2016.132
38. Izquierdo-Lahuerta A Martínez-García C Medina-Gómez G Lipotoxicity as a trigger factor of renal disease J. Nephrol. 2016 29 603 610 10.1007/s40620-016-0278-5 26956132
Izquierdo-Lahuerta, A., Martínez-García, C. & Medina-Gómez, G. Lipotoxicity as a trigger factor of renal disease. J. Nephrol. 29, 603–610 (2016).26956132 10.1007/s40620-016-0278-5
